IDEXX Laboratories, Inc. vs NextEra Energy, Inc. — how do they compare? IDEXX Laboratories, Inc. trades at $512.76 (market cap $40.43B), while NextEra Energy, Inc. trades at $77.36 (market cap $161.39B). The key difference: NextEra Energy, Inc. is far larger — about 4× IDEXX Laboratories, Inc.'s market cap, and NextEra Energy, Inc. pays a 3.22% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and NextEra Energy, Inc. for 83 Days on average.
| IDXX | NEE | |
|---|---|---|
Market Cap | $40.43B | $161.39B |
Volume | 692,164 | 11,780,955 |
Sector | Health | Utilities |
52-Week High | $766.68 | $97.88 |
52-Week Low | $504.70 | $75.49 |
Typical Hold Time | 46 Days | 83 Days |
Enterprise Value | $41.32B | $268.72B |
Dividend Yield | — | 3.22% |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $506.67, down 1.7% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $4.27 exceeding expectations of $3.94. Recent developments include the acquisition of CoVetAI to enhance veterinary workflow intelligence and expansion of diagnostic testing platforms internationally. Revenue growth remains robust at $4.3 billion for 2025, with net income margins exceeding 25%.
The stock presents a compelling growth story with strong profitability metrics and analyst consensus pointing to significant upside potential (average price target $665). However, current technical weakness and premium valuations (P/E 36.06) create near-term headwinds. Key risks include foreign exchange pressures and potential slowdown in U.S. veterinary visits, while institutional ownership trends show mixed positioning among major funds.
NextEra Energy (NEE) trades at $77.06, down 1.05% today, near its 52-week low of $74.78. The stock shows mixed signals with a bearish technical outlook but strong fundamentals, including a 32.4% net income margin and recent earnings beats. Recent news highlights growth initiatives like the Project Star energy infrastructure partnership and a dividend of $0.62 payable in September 2026.
NEE offers a compelling valuation with a P/E of 17.39 and a consensus price target of $96, implying 25% upside. Risks include high debt levels and interest rate sensitivity, but analyst sentiment remains bullish with 66.7% buy ratings. The stock is positioned for long-term growth in clean energy, though near-term volatility may persist.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →